Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 38Neoplasm Metastasis 9Brain Neoplasms 6Stomach Neoplasms 3Colorectal Neoplasms 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 2Recurrence 2Neoplasms 2Neoplasm, Residual 2Meningeal Carcinomatosis 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Cancer With Brain Metastasis 2Salivary Gland Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Inflammatory Breast Neoplasms 1HER2-positive Breast Cancer 1HER2-negative Breast Cancer 1HER2 Overexpression 1Glioblastoma 1Gastric Adenocarcinoma 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1Breast Cancer Metastatic 1Adenocarcinoma Of Esophagus 1

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2 Overexpression × trastuzumab deruxtecan × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡